Scientists have identified SLAMF6 as a key suppressor of T cell immunity against cancer and developed monoclonal antibodies that neutralize it in mice, published in Nature. Biotechnology company Replimune Group has reported its 2026 financial position, with a market value of approximately $234.5 million and ongoing clinical trials.
Multiple recent studies evaluate different immunotherapy approaches for advanced NSCLC, including long-term benefits for nivolumab plus ipilimumab with chemotherapy in PD-L1-negative tumors, limited advantages from PD-(L)1 rechallenge strategies, and early positive signals from combining TIGIT and PD-1 inhibitors in PD-L1-high patients.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
ABL111 received FDA agreement on an accelerated approval pathway for metastatic gastric cancer as the first patient was dosed in a global phase 2 trial. The companies said ORR will support accelerated approval and phase 2 is evaluating ABL111 with nivolumab and mFOLFOX6.
